Quick Facts: Main Therapeutic Domains

• Supports relief of hot flushes and night sweats associated with menopause.
• Intended for the short-term management of menopausal symptoms.
• A treatment option for addressing bone density changes postmenopause.

Sandrena 0.1% is an established option within Hormone Replacement Therapy (HRT) for postmenopausal individuals. The primary therapeutic use is to provide support for the relief of symptoms related to estrogen deficiency following natural or surgical menopause. This may include helping to manage vasomotor symptoms, such as hot flushes (also known as hot flashes) and night sweats, which can impact daily functioning and rest.

The medication is also indicated for the prevention of postmenopausal osteoporosis. It is considered a relevant treatment choice for individuals identified as having a high risk of future fractures who are not able to use or have contraindications for other approved medicines for osteoporosis prevention. The general goal of this treatment is to help maintain bone density and support overall quality of life.

Who Can and Cannot Use Sandrena 0.1%?

The eligibility for Sandrena 0.1% (estradiol gel) is strictly defined by regulatory authorities and centers on life stage and specific health history.

---

Approved and Restricted Populations

Sandrena 0.1% is officially allowed for postmenopausal women to treat estrogen deficiency symptoms. For women with an intact uterus, the use of this estrogen-alone therapy is conditional; it must be combined with a progestogen for an adequate duration to reduce the risk of endometrial hyperplasia.

Age-Related Eligibility	Status (Regulatory Classification)
Pediatric Population	Use is not indicated or not established
Geriatric Population	Experience in women over 65 years is limited

---

Absolute Contraindications (Must Not Use)

The medicine is contraindicated and must not be used if a patient has or has a history of the following conditions, as stated in the product label:

• Known or suspected estrogen-dependent cancers (e.g., breast cancer or endometrial cancer).
• Active or history of venous thromboembolism (VTE), including DVT or Pulmonary Embolism (PE), or arterial thromboembolic disease (e.g., MI or stroke).
• Undiagnosed abnormal genital bleeding.
• Acute liver disease or liver function that has not returned to normal.
• Pregnancy or suspected pregnancy.

The regulatory documentation for Sandrena 0.1% establishes the product's interaction profile based on pharmacokinetic alterations and specific contraindicated combinations. The primary pharmacokinetic mechanism involves the CYP3A4 enzyme system, which is documented to metabolize estradiol.

CYP3A4 Inducers (e.g., rifampicin, certain antiepileptics like carbamazepine, and the herbal supplement St. John's Wort) may increase the metabolism of estradiol, resulting in reduced plasma concentrations. Conversely, CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, and grapefruit juice) can decrease metabolism, potentially leading to increased plasma concentrations.

Certain combination medicines for Hepatitis C Virus (HCV), including regimens containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir, or glecaprevir/pibrentasvir, are formally classified as contraindicated due to the documented risk of elevated liver enzymes.

The product may also alter the efficacy of other medicines; it is documented to reduce the effectiveness of co-administered antihypertensives and oral hypoglycaemics. A functional interaction exists with Thyroid Replacement Therapy agents, where estradiol can increase Thyroid Binding Globulin (TBG), an interaction that necessitates the monitoring of thyroid function for patients on these medicines.

Mechanism of Action: Estradiol's Pharmacodynamics

Sandrena 0.1% delivers estradiol transdermally, enabling the active hormone to enter the systemic circulation and interact directly with its biological targets. Estradiol functions as an agonist for the intracellular Estrogen Receptors ( ERalpha and ERbeta) found in target tissues, including the hypothalamus, bone, and vasculature.

Upon binding, the activated receptor complex translocates to the cell nucleus, initiating a genomic signaling cascade that modulates the transcription of specific genes. This results in altered synthesis of proteins that govern cellular processes across multiple systems. Central action includes the influencing of activity within the hypothalamic thermoregulatory center, modifying the subsequent cascade of signals that regulate peripheral vasomotor responses.

Peripherally, the mechanism involves inhibition of osteoclast activity (bone resorption) within the skeletal system, which contributes to the regulation of bone mineral content. It further affects the vascular system by modulating endothelial function and microcirculatory activity, primarily through non-genomic pathways that influence vascular tone.

Administration Guidelines

Sandrena 0.1% (estradiol gel) is intended for transdermal use and is applied once daily.

---

Dosing and Frequency

Category	Instruction
Route of Administration	Transdermal (applied to the skin)
Usual Starting Dose	1.0 mg estradiol (1.0 g gel) once daily
Maintenance Range	0.5 mg to 1.5 mg estradiol per day, adjusted after 2 to 3 cycles based on clinical response
Treatment Pattern	Can be used continuously (daily) or cyclically (with planned breaks)
Missed Dose Rule	If the delay is not more than 12 hours, apply the dose immediately; otherwise, skip the dose and resume the next day

---

Procedural Requirements

1. Preparation and Site: The gel must be applied to clean and dry skin of the lower trunk or the thigh. The application site should be alternated between the left and right side daily, and the gel should be spread over an area 1 to 2 times the size of a hand.
2. Drying and Contact: The gel must be allowed to dry for a few minutes. The application site should not be washed for at least 1 hour after application. Hands must be washed with soap and water immediately after use to prevent accidental transfer.
3. Progestogen Combination: For women with an intact uterus, the protocol requires the combination of the estradiol gel with an adequate dose of progestogen for a minimum of 12 to 14 consecutive days per month/28-day cycle. The addition of progestogen is generally not recommended for hysterectomised women unless there is a diagnosis of endometriosis.

These instructions define the standardized application and required co-medication protocol for the administration of Sandrena 0.1%.

Research Evidence / Overview of Studies

Mechanism of Action

Studies have investigated the proposed biological action of the drug. Research includes exploration into the drug's activity concerning chemical pathways, indicating its function as an estrogen receptor agonist.

Efficacy and Symptom Management

Studies have investigated the relationship between the drug's administration and reported symptoms in adults with this condition, specifically moderate to severe vasomotor symptoms (e.g., hot flashes and night sweats). Research explored the association between drug use and measures of pain, including time to reported onset of effects. Overall, this treatment approach has been explored in several studies.

---

Combination Therapy Research

The evidence from studies examined this combination’s use (Estradiol and Progestogen). Studies investigated whether the combination was associated with long-term changes in symptoms and compared the findings to monotherapy. Research has examined whether this combination therapy is associated with changes in patient outcomes.

• RCT Findings: A 12-week, randomized, placebo-controlled, double-blind Phase 3 study evaluated the relative effect of the gel compared to a placebo. This trial reported findings that participants receiving the drug had lower average symptom severity scores compared to the placebo group. Treatment was associated with reductions in the frequency and severity of vasomotor symptoms from baseline, regardless of a woman's age or uterine status.
• Safety Profile: Studies have evaluated the safety profile of the drug in adults with this condition. Studies compared the reported frequency of side effects for this therapy versus other comparative agents. Transdermal administration is associated with a different ratio of metabolites (estrone to estradiol) compared to oral administration.
• Drug Interactions: Studies have evaluated the effects of co-administering the drug with substances such as alcohol or grapefruit products, as well as with certain medications like those for epilepsy or tuberculosis.

Key Studies & References

1. Estradiol Gel 0.1% Relieves Vasomotor Symptoms Independent of Age, Ovarian Status, or Uterine Status (Post-hoc Analysis of Phase 3 Trial)
2. The 2022 hormone therapy position statement of The North American Menopause Society (NAMS)

Common questions about Sandrena 0.1% (FAQ)

---

Q: How does the transdermal delivery of Sandrena 0.1% differ from taking an oral estrogen tablet?

A: Transdermal application, which is the method used for Sandrena 0.1% gel, is studied to provide hormone replacement that avoids the first-pass metabolism effect. This term refers to the process where a substance taken orally is metabolized by the liver before it enters the systemic circulation. Avoiding this process is noted as a characteristic of transdermal delivery in regulatory information.

Q: Why is it important not to rub the gel in too hard during application?

A: Official instructions state that the gel should be smoothed thinly over the application area and allowed to air dry rather than being rubbed in hard. Following the regulatory application method is advised to support the intended rate and amount of absorption.

Q: Is there a specific amount of skin area the gel should cover for proper absorption?

A: Yes, official procedural guidelines describe the application surface as being spread over an area that is 1 to 2 times the size of an average adult hand. This guidance is provided to support the intended absorption of the gel into the bloodstream.

Q: How long does the gel usually take to dry after being spread on the skin?

A: Regulatory instructions state that the gel should be allowed to dry for a few minutes after being spread on the skin. Official instructions indicate the gel should be allowed to fully dry before getting dressed or engaging in activities that could cause the gel to rub off.

Q: What happens if the application site gets wet or sweaty too soon after using the gel?

A: To ensure proper absorption, the application site should not be washed for at least 1 hour after applying the gel, according to official guidelines. The rule is in place because getting the site wet too soon may affect the amount of medicine that is absorbed into the body.

Q: How long does it typically take to start feeling the intended effects of Sandrena 0.1%?

A: Regulatory information indicates that dosage adjustments and the assessment of clinical response are typically considered after two to three treatment cycles (months). Official guidance emphasizes that patients attend scheduled appointments to monitor symptoms and discuss progress.

Q: What are the most common reported side effects associated with Sandrena 0.1% use?

A: Official documents classify the most commonly reported adverse reactions as those that may affect up to 1 in 10 people. These include headache, nausea, abdominal pain, breast pain or tenderness, local application site reactions, and weight changes.

Q: Does the use of Sandrena 0.1% have a documented impact on weight changes?

A: Yes, regulatory documents list weight changes as a common adverse reaction associated with Sandrena 0.1% use. This is a general term for a change in body weight that has been reported in clinical use.

Q: Is there a documented link between Sandrena 0.1% use and an increase in headaches or migraines?

A: Both headache and migraine are listed as documented adverse reactions in official product information. Headache is classified as a common reaction, while migraine is also listed as a common reported side effect.

Q: Can Sandrena 0.1% be accidentally transferred to a partner or child through physical contact?

A: Yes, accidental transfer of the estradiol gel to others (including children, partners, or pets) through close skin contact is documented as a possibility if precautions are not taken. Regulatory guidance includes steps to minimize this risk, such as washing hands immediately after use.

Q: How long after application must physical contact with the application site be avoided to prevent transfer?

A: Regulatory guidance advises covering the application area with clothing as soon as the gel has dried to prevent accidental transfer of the product to others. This measure is intended to minimize contact with the dried application site.

Q: Are there specific non-prescription supplements known to interact with Sandrena 0.1%?

A: Yes, regulatory documents specifically list the herbal supplement St. John's Wort as a CYP3A4 inducer. This means it may cause a reduction in the plasma concentration of estradiol, potentially interfering with how Sandrena 0.1% works.

Q: Are there specific classes of prescription medications known to interfere with how Sandrena 0.1% works?

A: Official documents specify that medicines classified as CYP3A4 inducers or inhibitors may interact with Sandrena 0.1%. Additionally, certain combination medicines used for Hepatitis C Virus (HCV) are formally classified as contraindicated due to the risk of elevated liver enzymes.

Q: What is the official guidance on using Sandrena 0.1% while taking thyroid hormones?

A: Estradiol may increase Thyroid Binding Globulin (TBG), a protein that carries thyroid hormone in the blood. Official documentation indicates that the monitoring of thyroid function is required for patients using thyroid replacement therapy.

Q: Is Sandrena 0.1% suitable for use by individuals over the age of 65?

A: Official documentation notes that experience with Sandrena 0.1% in women over 65 years of age is limited. The use of Hormone Replacement Therapy always involves an assessment of individual risks and benefits.

Q: Why is Sandrena 0.1% available in two different strengths (0.5 mg and 1.0 mg) if it's a 0.1% gel?

A: The medicine is packaged in separate 0.5 mg and 1.0 mg estradiol sachets to allow for the regulatory maintenance dosage range. This allows the daily dose to be adjusted from 0.5 mg up to 1.5 mg per day based on individual clinical response.

Q: What happens if Sandrena 0.1% does not seem to be helping symptoms after the first few weeks?

A: Regulatory documentation specifies that the dosage can be readjusted after two to three cycles based on clinical response. Official guidance indicates patients should attend scheduled appointments to check progress and discuss symptom relief with their prescribing professional.

Q: Do studies exist on the long-term effectiveness of Sandrena 0.1% for menopausal complaints?

A: Official guidance recommends that the need for continued treatment should be reviewed after 6 months, taking into account the risk-benefit ratio for the individual patient. This scheduled review process is the mechanism for assessing whether the therapy remains appropriate over time.

Q: What are the signs of potential accidental overdose listed in the official patient information?

A: Signs of using too much of the medicine are listed in the patient information leaflet. These may include feeling bloated, anxious or irritable, breast tenderness, nausea, vomiting, and withdrawal bleeding.

Q: Does alcohol consumption affect the absorption or effectiveness of Sandrena 0.1%?

A: While specific product information for Sandrena 0.1% does not list a direct interaction with alcohol, general research has explored the possibility that moderate alcohol consumption may temporarily increase estradiol levels in women receiving Hormone Replacement Therapy.

Q: Is Sandrena 0.1% used for purposes other than menopausal symptom relief in official documentation?

A: Official documentation states that Sandrena 0.1% is indicated for the treatment of climacteric symptoms (like hot flashes) following natural or surgical menopause. Its therapeutic purpose is strictly defined as hormone restoration for estrogen deficiency states.

Q: How often is the need for continued treatment with Sandrena 0.1% reviewed by medical professionals according to guidelines?

A: Official guidance recommends reviewing the need for continuation of treatment after 6 months. Furthermore, patients are advised to attend regular progress check-ups, which may occur every three to six months.

Q: Can Sandrena 0.1% be stored at room temperature, or does it need refrigeration?

A: Official storage instructions state that the gel should be stored at room temperature (below 25 C), and refrigeration is not required. Regulatory information also specifies that the medicine should be kept out of the sight and reach of children.

How to Store and Dispose of Sandrena 0.1%

Sandrena 0.1% transdermal gel must be stored according to specific regulatory conditions to maintain its stability.

Storage & Disposal Entity	Official Regulatory Requirement
Maximum Storage Temperature	Do not store above 25 °C
Shelf-Life	3 years (when stored correctly)
Child Safety	Keep out of the sight and reach of children
Disposal	Must be disposed of in accordance with local requirements
Environmental Warning	May pose a risk to the aquatic environment

The official labeling mandates a maximum temperature limit to preserve the product's 3-year shelf-life. The gel is supplied in single-dose aluminum foil containers and must be secured away from children. All unused or expired medicinal product and waste material must be handled according to local waste protocols, as the product is documented as a potential risk to the aquatic environment.